Jim Simons’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Jim Simons’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-586,294	Closed	-$510K	–	3853
2019 Q2	$510K	Buy	586,294 +281,094	+92%	+$440K	﹤0.01%	2987
2019 Q1	$708K	Buy	305,200 +186,600	+157%	+$506K	﹤0.01%	2813
2018 Q4	$275K	Buy	+118,600	New	+$1.05M	﹤0.01%	3050

Other funds holding SNNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Jim Simons's SNNA Position: Q3 2019 in Review

Jim Simons sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q3 2019, closing a stake of 586,294 shares — an estimated $510K sold.

Jim Simons first reported a position in SNNA in Q4 2018 and held it in 3 quarters. The position peaked at $708K in Q1 2019. 23 funds tracked by Wall St. Rank hold SNNA as of Q3 2019.

Jim Simons reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Jim Simons sold 586,294 Sienna Biopharmaceuticals, Inc. shares in Q3 2019, an estimated $510K.
Jim Simons first reported a position in Sienna Biopharmaceuticals, Inc. in Q4 2018 and held it in 3 quarters.
Jim Simons's Sienna Biopharmaceuticals, Inc. position peaked at $708K in Q1 2019.
23 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q3 2019.

Based on Renaissance Technologies's 13F filing for Q3 2019, filed 13 Nov 2019.